Cognizant

While there are many successes to show for its decades of development, there remain four substantial problems that impede the velocity with which cell and gene therapies can be brought to market. Despite the intricacies of these issues, there are emerging solutions to address them. If the biopharma industry can develop these solutions on a broad scale, cell and gene technologies can accelerate and fulfill the early promise of regenerative medicine.

Digital health platforms, modern delivery models, and edge technologies can transform the way life sciences companies create a virtuous circle of value generation, equipping patients with capabilities that improve health outcomes while providing businesses with valuable data and insights to drive new research, improve stakeholders’ experiences, and accelerate growth. Solutions designed to serve clinical trial participants outside of a clinical setting should be considered as companion services for commercial therapies to drive greater adherence as well as real-world evidence.

Wednesday, September 28, 2022, 11 am ET Join this webinar to hear industry thought leaders discuss issues that impede cell and gene therapy development. They will cover new approaches for expanding viral vector manufacturing capacity with appropriate quality, share recommendations for streamlining clinical trial design and process development, explore opportunities for adapting the regulatory framework for cell and gene therapy technologies, and examine innovative pricing and contracting models.

Thursday, July 21st 2022 at 11am EST, 8am PST, 5pm CEST Join this webinar to hear industry thought leaders discuss how data and experiences serve clinical and commercial needs, explore which platforms and technologies can enable a robust digital health ecosystem, and share recommendations for building a digital health strategy fit for your business.

Thursday, March 24, 2022 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET Join this webinar to hear industry thought leaders discuss the process and building blocks of end-to-end clinical development, explore the essential elements of a unified clinical platform, and share the benefits and challenges involved in realizing the vision of a unified clinical platform.